臨床泌尿器科63巻5号

2009年04月発行

特集 泌尿器科の癌薬物療法―ここが聞きたい

腎癌―分子標的治療薬時代のサイトカイン療法の役割

著者： 岸田健¹ 矢尾正祐²

所属機関： ¹神奈川県立がんセンター泌尿器科 ²横浜市立大学附属病院泌尿器科

ページ範囲：P.301 - P.309

文献概要

要旨　分子標的薬は大規模臨床試験という質の高いエビデンスを基にその有用性が評価されており，EBMの考えに基づけばサイトカイン療法に対する優位性はゆるぎないもののように思われる。しかしながら，EBMの本質は多種多様な患者に合わせてエビデンスを取捨選択し適応していくものであり，数少ないながらもCR（complete response）症例が得られるサイトカイン療法を否定するものではない。今後はサイトカイン療法と分子標的療法の適応を選別するための効果予想因子，つまりバイオマーカーの同定により，個々の治療の奏効性を高めるとともに，両者の交替療法，併用療法などを試みることによって個々の患者に合わせたきめ細かい治療の選択が求められ，その中でサイトカイン療法の役割は維持されていくと予想される。

参考文献

1）Latif F, Gnarra J and Yao M：Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260：1317-1320, 1993

2）福井次矢（編）：EBM実践ガイド．医学書院，東京，1999

3）斉尾武郎：Evidence-based medicineの現代科学論的考察．Clin Eval 29：185-201，2001

4）桑島　厳：大規模臨床試験結果を正しく評価するために．（http://www.lifescience.jp/ebm/wadai/0411/index.html）

5）Motzer RJ, Hutson TE, Tomczak P, et al：Sunitinib versus Interferon alfa in metastatic renal-cellcarcinoma. N Engl J Med 356：115-124, 2007

6）Escudier B, Eisen T, Stadler WM, et al：Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356：125-134, 2007

7）Hudes G, Carducci M, Tomczak P, et al：Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356：2271-2281, 2007

8）Rini BI, Halabi S, Rosenberg JE, et al：Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma. J Clin Oncol 26：5422-5428, 2008

9）Motzer RJ, Escudier B, Oudard S, et al：Efficacy of everolimus in advanced renal cell carcinoma：a double-blind, randomised, placebo-controlled phase Ⅲ trial. Lancet 372：449-456, 2008

10）Cella D, Li JZ, Cappelleri JC, et al：Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa：results from a phase Ⅲ randomized trial. J Clin Oncol 26：3763-3769, 2008

11）Bukowski R, Cella D, Gondek K, et al：Effects of sorafenib on symptoms and quality of life：results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30：220-227, 2007

12）Remák E, Charbonneau C, Négrier S, et al：Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Clin Oncol 26：3995-4000, 2008

13）日本泌尿器科学会腎がん診療ガイドライン作成委員会編：腎がん診療ガイドライン．（http://jsco-cpg.jp/item/10/index.html）

14）Pyrhönen S, Salminen E, Ruutu M, et al：Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone inpatients with advanced renal cell cancer. J Clin Oncol 17：2859-2867, 1999

15）Medical Research Council Renal Cancer Collaborators：Interferon-alpha and survival in metastatic renal carcinoma：early results of a randomized controlled trial. Lancet 353：14-17, 1999

16）Gleave ME , Elhilali M, Fradet Y, et al：Interferon gamma-1β compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338：1265-1271, 1998

17）Negrier S, Escudier B, Lasset C, et al：Recombinant human inerleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francaisd' Immunotherapie. N Engl J Med 338：1272-1278, 1998

18）Atzpodien J, Hoffmann R, Franzke M, et al：Thirteen-year, long-term efficacy of interferon 2 alpha and interleukin2-based home therapy inpatients with advanced renal cell carcinoma. Cancer 95：1045-1050, 2002

19）Messing EM, Manola J, Wilding G, et al：Phase Ⅲ study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma：an Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 21：1214-1222, 2003

20）Clark JI, Atkins MB, Urba WJ, et al：Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma：a cytokine working group randomized trial. J Clin Oncol 21：3133-3140, 2003

21）Atzpodien J, Schmitt E, Gertenbach U, et al：Adjuvant treatment with interleukin-2 and interferon-alpha 2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy：results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group（DGCIN）. Br J Cancer 92：843-846, 2005

22）Steineck G, Strander H, Carbin BE, et al：Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma：a randomized trial. Acta Oncol 29：155-162, 1990

23）Ritchie AWS, Griffiths G, Cook P, et al：Alpha interferon improves survival in patients with metastatic renal cell carcinoma：preliminary results of an MRC randomized trial. Proc Am Assoc Clin Oncol 17：310a, 1998

24）Pyrhönen S, Salminen E, Lehtonen T, et al：Recombinant interferon alpha-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma：a phase Ⅲ study. Proc Am Assoc Clin Oncol 15：244a. 1996

25）Kriegmar M, Oberneder R and Hofstetter A：Interferon alpha and vinblastine versus medroxy-progesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45：758-762, 1998

26）Coppin C, Porzsolt F, Autenrieth M, et al：Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews, Issue 3, 2004

27）Fyfe G, Fisher RI, Rosenberg SA, et al：Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13：688-696, 1995

28）Fisher RI, Rosenberg SA and Fyfe G：Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6（Suppl 1）：S55-57, 2000

29）Negrier S, Escudier B, Lasset C, et al：Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal cell carcinoma. Groupe Francais d' Immunotherapie. N Engl J Med 338：1272-1278, 1998

30）Yang JC, Sherry RM, Stienberg SM, et al：A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol 21：3127-3132, 2003

31）McDermott DF, Regan MM, Clark JI, et al：Randomized phase Ⅲ trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23：133-141, 2005

32）McDermott DF and Atkins MB：Interleukin-2 therapy of metastatic renal cell carcinoma-predictors of resonse. Semin Oncol 33：583-587, 2006

33）McDermott DF and Atkins MB：Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 4：455-468, 2004

34）Motzer RJ, Bacik J, Murphy BA, et al：Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20：289-296, 2002

35）Negrier S, Caty A, Lesimple T, et al：Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18：4009-4015, 2000

36）Figlin R, Gitlitz B, Franklin J, et al：Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma：an analysis of 203 consecutively treated patients. Cancer J Sci Am 3（Suppl 1）：S92-97, 1997

37）Leibovich BC, Han KR, Bui MH, et al：Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma：a stratification tool for prospective clinical trials. Cancer 98：2566-2575, 2003

38）Akaza H, Tsukamoto T, Onishi T, et al：A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma：a multicenter open study. Int J Clin Oncol 11：434-440, 2006

39）Upton MP, Parker RA, Youmans A, et al：Histologic predictors of renal cell carcinoma（RCC）response to interleukin-2 based therapy. Proc Am Soc Clin Oncol 22：851A, 2003

40）Bui MH, Seligson D, Han KR, et al：Carbonic anhydrase Ⅸ is anindependent predictor of survival in advanced renal clear cell carcinoma：implications for prognosis and therapy. Clin Cancer Res 9：802-811, 2003

41）Atkins M, McDermott D, Mier J, et al：Carbonic anhydrase Ⅸ（CA Ⅸ）expression predicts for renal cell cancer（RCC）patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol 23：383A, 2004

42）Atkins M, Regan M, McDermott D, et al：Carbonic anhydrase Ⅸ expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11：3714-3721, 2005

43）Ito N, Eto M, Nakamura E, et al：STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 25：2785-2791, 2007

44）Passalacqua R, Buti S, Tomasello G, et al：Immunotherapy options in metastatic renal cell cancer：where we are and where we are going. Expert Rev Anticancer Ther 6：1459-1472, 2006

45）Porta C, Paglino C, Imarisio I, et al：Cyatokine based immunotherapy for advanced kidney cancer：past results and future perspectives in the era of molecularly targeted agents. The Scientific World Journal 7：837-849, 2007

46）Mulder SF, van Spronsen DJ and De Mulder PH：Do the results of the new trials change the standard treatment of metastatic renal cell cancer? Onkologie 30：260-264, 2007